News
-
-
PRESS RELEASE
Jaguar Health Completes Submission of New Animal Drug Application for Full FDA Approval of Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
Jaguar submits NADA for Canalevia-CA1 to FDA for CID in dogs, reporting positive results in study. Crofelemer effectively treats chemotherapy-induced diarrhea -
-
PRESS RELEASE
Jaguar Health Announces Plan to Explore Strategic Alternatives Aligned with Targeted NDA Filing for Rare Disease Intestinal Failure Program
Jaguar Health, Inc. to explore strategic alternatives maximizing stockholder value. Updates on crofelemer program for rare intestinal failure diseases by CEO Lisa Conte at Life Sciences Virtual Investor Forum on June 24, 2026 -
-
PRESS RELEASE
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Announces Positive Results of Preclinical Study of Coca for Weight Gain Prevention
Magdalena's drug candidate, a coca leaf extract, shows promise for post-GLP-1 weight loss management. Preclinical study results suggest potential as weight maintenance therapy -
-
PRESS RELEASE
Jaguar Health Presenting June 24, 2026 at the Life Sciences Virtual Investor Forum to Provide Updates on Company's Crofelemer Development Program for Rare Intestinal Failure Diseases
Jaguar Health, Inc. announces virtual presentation by CEO Lisa Conte at Life Sciences Virtual Investor Forum on June 24, 2026. Crofelemer presentations at ESPGHAN Meeting -
-
